Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

Cipla receives USFDA approval for its generic cancer treatment drug, paclitaxel protein-bound particles, a therapeutic ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. Click here to find out why RVMD ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

Autopsy demonstrated extensive metastatic carcinoma of the endometrium ... hematogenous spread throughout the lungs, obliterating lung structure in many areas. Comparison of the tumor at autopsy ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...